Stevanato Group (STVN) Stock Overview
Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for STVN from our risk checks.
STVN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Stevanato Group S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.51 |
| 52 Week High | US$28.00 |
| 52 Week Low | US$12.89 |
| Beta | 0.78 |
| 1 Month Change | -8.23% |
| 3 Month Change | 8.40% |
| 1 Year Change | -31.49% |
| 3 Year Change | -48.92% |
| 5 Year Change | n/a |
| Change since IPO | -16.07% |
Recent News & Updates
Narrative Update • Jun 15
STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power
Analysts have trimmed their price target on Stevanato Group to about $24.39 from $24.81, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E. Recent Street research has also highlighted the company’s exposure to biologics and GLP-1 related demand.Seeking Alpha • Jun 11
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
Summary Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes. Margin expansion, operational leverage from new facilities, and growth are not well reflected in the current valuation. We reiterate our buy rating. Read the full article on Seeking AlphaRecent updates
Narrative Update • Jun 15
STVN: GLP-1 Exposure And Biologics Focus Will Support Future Earnings Power
Analysts have trimmed their price target on Stevanato Group to about $24.39 from $24.81, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E. Recent Street research has also highlighted the company’s exposure to biologics and GLP-1 related demand.Seeking Alpha • Jun 11
Stevanato: HVS Momentum Overshadows Engineering Weakness, Offering Compelling Upside
Summary Stevanato Group is reiterated as a Buy, driven by robust Q1 results and a compelling long-term growth trajectory. The High-Value Solutions segment accelerated, now comprising 47% of sales, fueled by broad biologics and injectable therapies demand. Management attributed the slowdown in the Engineering segment to project timing and order delays rather than competitive pressure or deteriorating demand. Importantly, segment profitability improved despite lower volumes. Margin expansion, operational leverage from new facilities, and growth are not well reflected in the current valuation. We reiterate our buy rating. Read the full article on Seeking Alpha
Narrative Update • Jun 01
STVN: Biologics Strength And GLP-1 Exposure Will Balance Execution Risks
Narrative Update Analysts have trimmed their average price targets for Stevanato Group by several dollars per share, generally moving into a $19 to $32 range as updated models reflect Q4 results, revised GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research points to a more cautious tone around Stevanato Group, with several price targets reset into a tighter band even after Q4 results came in ahead of some expectations.Narrative Update • May 08
STVN: Core Biologics Shift Will Support Future Earnings Power Despite Guidance Reset
Narrative Update Analysts have trimmed Stevanato Group's average price target to reflect the recent cuts to $19, $26, $28 and $32, with updated models indicating a fair value estimate of about $24.81. This is based on slightly lower margin assumptions, a modest adjustment to long term growth, a somewhat lower discount rate, and a higher expected future P/E multiple.Narrative Update • Apr 23
STVN: Core Biologics Shift Will Drive Future Earnings Power
Analysts have trimmed their Stevanato Group price targets by several dollars across the Street, now clustering in a $19 to $32 range, as they refresh models after Q4 results and factor in slightly lower long term margin, growth, and P/E assumptions, alongside shifting expectations for GLP-1 and core biologics revenue contributions. Analyst Commentary Recent research updates show analysts marking down their price targets but still drawing a clear line between near term noise and the longer term setup for Stevanato Group, especially around GLP-1 exposure and the broader biologics portfolio.Narrative Update • Apr 09
STVN: Biologics And GLP-1 Exposure Will Support Future Upside Potential
Analysts have trimmed the Stevanato Group fair value estimate from $18.09 to $17.50 after a series of reduced Street price targets, citing updated models post Q4 results, a higher discount rate, slightly softer revenue growth and margin assumptions, and a higher future P/E multiple that still reflects support for the core biologics and GLP-1 exposure. Analyst Commentary Recent Street research has largely centered on resetting expectations after Q4, with several bearish analysts trimming price targets while still recognizing the support from biologics and GLP-1 exposure.
Narrative Update • Mar 26
STVN: Biologics Focus And On Body Delivery Collaboration Will Drive Future Cash Flows
Analyst price targets for Stevanato Group have been reduced across several firms, with cuts ranging from $5.50 to $8 per share as analysts factor in updated Q4 results, a shift in GLP-1 growth expectations, and a greater focus on the core biologics and engineering businesses. Analyst Commentary Recent Street research on Stevanato Group reflects a mix of reduced price targets and generally supportive views on the company’s execution in biologics, premium formats, and GLP-1 related revenue.Narrative Update • Mar 11
STVN: Biologics Mix Shift And On Body Delivery Partnership Will Support Future Cash Flows
Analysts have trimmed their consolidated price target on Stevanato Group by $4.09 to $32.00. This reflects updated models after Q4 results, slightly lower fair value assumptions, modestly higher discount rates, and more measured expectations for revenue growth, profit margins, and future P/E, even as they continue to highlight strength in GLP-1 and broader biologics demand.Narrative Update • Feb 25
STVN: Large-Volume Self-Administration Partnership Will Support Future Upside Potential
Analysts have trimmed their 12 month price target on Stevanato Group by about $4.90 per share to reflect updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E multiples, citing recent Street research calls that include Jefferies cutting its target by $5.50. Analyst Commentary Bearish analysts are signaling a more cautious stance on Stevanato Group, reflected in reduced 12 month price targets that factor in updated views on fair value, discount rates, revenue growth, profit margins, and future P/E multiples.Narrative Update • Feb 09
STVN: Large Volume On-Body Delivery Partnership Will Support Stronger Future Cash Flows
Analysts have nudged their fair value estimate for Stevanato Group slightly higher to US$36.09, citing small adjustments to discount rate assumptions, revenue growth outlook, profit margin expectations, and a refined future P/E framework. What's in the News Datwyler, LTS Device Technologies and Stevanato Group entered a collaboration focused on large volume subcutaneous drug delivery using on-body administration for larger dose volumes (Key Developments).Analysis Article • Feb 04
Why We're Not Concerned Yet About Stevanato Group S.p.A.'s (NYSE:STVN) 27% Share Price Plunge
Unfortunately for some shareholders, the Stevanato Group S.p.A. ( NYSE:STVN ) share price has dived 27% in the last...Narrative Update • Jan 26
STVN: Large Volume Drug Delivery Collaboration Will Support Stronger Future Cash Flows
Analysts have nudged their price target for Stevanato Group slightly higher to $36.08 from $36.05, citing updated assumptions for revenue growth, profit margins, and future P/E that modestly adjust their long term valuation. What's in the News Datwyler, LTS Device Technologies and Stevanato Group announced a collaboration focused on large volume subcutaneous drug delivery, targeting more convenient on body administration of larger doses for patients, with a joint platform to be presented at Pharmapack in Paris on January 21 to 22, 2026 (Key Developments).Narrative Update • Jan 11
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts now estimate Stevanato Group's fair value price target at approximately US$36.05, a very small adjustment from about US$36.08. This reflects updated views that combine slightly higher revenue growth expectations with modestly lower profit margin assumptions and a marginally higher future P/E outlook.Analysis Article • Jan 06
Are Stevanato Group S.p.A. (NYSE:STVN) Investors Paying Above The Intrinsic Value?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stevanato Group fair value estimate is US$16.36 Current share...Narrative Update • Dec 27
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Cash Flows
Analysts have nudged their price target on Stevanato Group slightly higher to approximately $36.08 per share from about $36.05, citing modestly stronger expectations for revenue growth and profit margins that more than offset a small anticipated decline in the company’s future price to earnings multiple. What's in the News Maintained 2025 revenue guidance, expecting between €1.160 billion and €1.190 billion, signaling confidence in demand and operational execution (Corporate Guidance) Announced a significant expansion of drug delivery system manufacturing capacity in Bad Oeynhausen, Germany, adding over 2,500 square meters of advanced production space to support global pharma and biotech customers (Business Expansions) Invested multi millions in an ISO 8 cleanroom environment equipped for injection molding and automated assembly, aimed at strengthening resilient, Europe based supply chains for partners (Business Expansions) Enhanced the Bad Oeynhausen site to scale production of key devices such as the Aidaptus autoinjector and Alina pen injector platforms, reinforcing the company’s role in patient centric combination products (Business Expansions) Valuation Changes Fair Value Estimate has risen slightly to approximately $36.08 per share from about $36.05.Narrative Update • Dec 12
STVN: Expanded Drug Delivery Capacity Will Support Stronger Future Profit Margins
Analysts have modestly trimmed their price target on Stevanato Group to approximately $36.05 from about $36.07, reflecting slightly higher perceived risk via a raised discount rate, which is only partly offset by improved profit margin expectations and a marginally lower forecast valuation multiple. What's in the News Maintained 2025 revenue guidance, with expected revenue in the range of €1.160 billion to €1.190 billion (Corporate guidance) Announced a significant expansion of drug delivery system manufacturing capacity at its Bad Oeynhausen, Germany facility, adding over 2,500 square meters of advanced production space (Business expansion) Invested multiple millions in a new ISO 8 cleanroom, injection molding, and automated assembly operations to support global pharma and biotech partners with resilient European supply chains (Business expansion) Strengthened production capabilities for key platforms, including the Aidaptus autoinjector and Alina pen injector, enhancing its role in patient centric combination products (Business expansion) Valuation Changes Fair Value Estimate: edged down slightly to approximately €36.05 from about €36.07 per share, reflecting a marginally lower intrinsic valuation.Narrative Update • Nov 25
STVN: German Facility Expansion Will Drive Stronger Supply Chain Integration
Analysts have slightly lowered their price target for Stevanato Group, adjusting the fair value from $28.80 to $28.78 based on minor updates to growth and profitability expectations. What's in the News Stevanato Group S.p.A. maintained its revenue guidance for 2025, expecting revenues in the range of €1.160 billion to €1.190 billion (Key Developments).Narrative Update • Nov 11
STVN: Expansion Of German Manufacturing Facility Will Fuel Future Upside
Narrative Update on Stevanato Group Price Target Analysts have raised their price target for Stevanato Group slightly, increasing it from $28.62 to $28.80. This change is attributed to modest improvements in projected revenue growth and profit margins, despite a higher discount rate.Analysis Article • Sep 22
Investors Interested In Stevanato Group S.p.A.'s (NYSE:STVN) Earnings
Stevanato Group S.p.A.'s ( NYSE:STVN ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong...Analysis Article • Aug 08
Here's What Analysts Are Forecasting For Stevanato Group S.p.A. (NYSE:STVN) After Its Second-Quarter Results
NYSE:STVN 1 Year Share Price vs Fair Value Explore Stevanato Group's Fair Values from the Community and select yours A...Analysis Article • Jun 23
Stevanato Group (NYSE:STVN) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • May 19
A Look At The Intrinsic Value Of Stevanato Group S.p.A. (NYSE:STVN)
Key Insights Stevanato Group's estimated fair value is US$21.37 based on 2 Stage Free Cash Flow to Equity With US$24.02...Analysis Article • Mar 26
Shareholders Should Be Pleased With Stevanato Group S.p.A.'s (NYSE:STVN) Price
With a price-to-earnings (or "P/E") ratio of 45.3x Stevanato Group S.p.A. ( NYSE:STVN ) may be sending very bearish...Seeking Alpha • Mar 09
Stevanato: Ramping Syringe Demand, Buy Confirmed
Summary Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues. Investments in expanding facilities in Latina and Fishers aim to meet rising product demand, and a significant sales increase is expected. Supportive CAPEX investment in different GEO provides downside protection in case of tariff war. Stevanato's valuation is supported by sales accelleration and EBITDA growth evolution. Read the full article on Seeking AlphaAnalysis Article • Feb 27
Is Stevanato Group (NYSE:STVN) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Feb 01
Calculating The Fair Value Of Stevanato Group S.p.A. (NYSE:STVN)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stevanato Group fair value estimate is US$22.37 Current share...Analysis Article • Dec 09
Stevanato Group S.p.A. (NYSE:STVN) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 46.1x Stevanato Group S.p.A. ( NYSE:STVN ) may be sending very bearish...
New Narrative • Nov 20
Engineering Optimization And Capacity Expansion To Unlock Growth Opportunities
Optimizing the Engineering segment and strategic shifts towards ready-to-use systems are expected to drive cost savings, improve margins, and boost productivity.Seeking Alpha • Nov 13
Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Summary Q3 2024 sales exceeded estimates, but adj. EBITDA and EPS fell short due to under-utilization and higher costs in the Engineering division. Despite temporary headwinds, we expect sequential margin improvement thanks to high-value solutions and new facilities ramp-up. Long-term growth remains strong, and Stevanato's economic moat remains intact. Looking ahead, we decided to maintain our buy rating target. Read the full article on Seeking AlphaAnalysis Article • Nov 12
Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think
The market rallied behind Stevanato Group S.p.A.'s ( NYSE:STVN ) stock, leading do a rise in the share price after its...Analysis Article • Nov 08
Stevanato Group S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models
It's been a pretty great week for Stevanato Group S.p.A. ( NYSE:STVN ) shareholders, with its shares surging 20% to...Analysis Article • Oct 23
We Think Stevanato Group (NYSE:STVN) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysis Article • Aug 21
Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$19.3 Based On Its Intrinsic Value?
Key Insights The projected fair value for Stevanato Group is US$15.75 based on 2 Stage Free Cash Flow to Equity...Analysis Article • Jul 25
Stevanato Group S.p.A. (NYSE:STVN) Looks Just Right With A 28% Price Jump
Those holding Stevanato Group S.p.A. ( NYSE:STVN ) shares would be relieved that the share price has rebounded 28% in...Analysis Article • Jul 23
Does Stevanato Group (NYSE:STVN) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • May 29
Stevanato: Destock Pressures, Long-Term Upside
Summary Stevanato revised its guidance for 2024 due to weaker-than-expected orders and clients' destocking activities. The company's Q1 results show decreased EBITDA and profit, causing investors to sell off shares. Here at the Lab, we remain confident in long-term prospects thanks to capacity expansion and biologics demand. STVN is not trading at a premium compared to its peers. Therefore, we reinstated a buy rating status. Read the full article on Seeking AlphaAnalysis Article • May 12
Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a sad week for Stevanato Group S.p.A. ( NYSE:STVN ), who've watched their investment drop 18% to US$21.82 in...Analysis Article • May 07
Stevanato Group S.p.A.'s (NYSE:STVN) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 46.5x Stevanato Group S.p.A. ( NYSE:STVN ) may be sending very bearish...Shareholder Returns
| STVN | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -8.8% | 0.3% | 2.2% |
| 1Y | -31.5% | 8.8% | 24.8% |
Return vs Industry: STVN underperformed the US Life Sciences industry which returned 8.8% over the past year.
Return vs Market: STVN underperformed the US Market which returned 24.8% over the past year.
Price Volatility
| STVN volatility | |
|---|---|
| STVN Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: STVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: STVN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 6,010 | Franco Stevanato | www.stevanatogroup.com |
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services.
Stevanato Group S.p.A. Fundamentals Summary
| STVN fundamental statistics | |
|---|---|
| Market cap | US$4.54b |
| Earnings (TTM) | US$164.17m |
| Revenue (TTM) | US$1.40b |
27.5x
P/E Ratio3.2x
P/S RatioIs STVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STVN income statement (TTM) | |
|---|---|
| Revenue | €1.20b |
| Cost of Revenue | €851.68m |
| Gross Profit | €351.58m |
| Other Expenses | €210.23m |
| Earnings | €141.35m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.52 |
| Gross Margin | 29.22% |
| Net Profit Margin | 11.75% |
| Debt/Equity Ratio | 28.3% |
How did STVN perform over the long term?
See historical performance and comparisonDividends
0.4%
Current Dividend Yield10%
Payout RatioDoes STVN pay a reliable dividends?
See STVN dividend history and benchmarks| Stevanato Group dividend dates | |
|---|---|
| Ex Dividend Date | Jun 11 2026 |
| Dividend Pay Date | Jul 29 2026 |
| Days until Ex dividend | 6 days |
| Days until Dividend pay date | 42 days |
Does STVN pay a reliable dividends?
See STVN dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 21:42 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stevanato Group S.p.A. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Curtis Moiles | BNP Paribas |
| Hugo Solvet | BNP Paribas |
| Michael Ryskin | BofA Global Research |